Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 29NIH 11NETWORK 8INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Pneumonia 1Leukemia, Myeloid, Acute 1Leukemia 1Esophagitis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Amifostine × Clear all
NCT00086099 2009-01-29

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

MedImmune LLC

Phase 1/2 Completed
54 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00081315 2007-08-21

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

MedImmune LLC

Phase 2 Completed
130 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Esophagitis, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡